Prediction: These 2 Stocks Could Soar in 2025
Small biotech companies sometimes see their shares skyrocket because of clinical or regulatory progress. That happened this year to Viking Therapeutics and Summit Therapeutics, which gained significant momentum following positive data readouts. Of course, it's hard to predict whose turn it will be in 2025, but there are clues we can follow to make educated guesses.
In that spirit, let's consider two biotech companies that could potentially deliver incredible returns next year: Recursion Pharmaceuticals (NASDAQ: RXRX) and BioAge Labs (NASDAQ: BIOA). Are these drugmakers worth investing in?
Recursion Pharmaceuticals is entering a crucial stretch in its history. The company's claim to fame is its artificial intelligence (AI)-powered operating system that tests clinical compounds against a library of human genes to identify the best candidates to send to clinical trials. Although Recursion Pharmaceuticals claims its approach could help significantly decrease the time and cost associated with developing novel medicines, it currently has no products on the market and no candidate in phase 3 studies. However, it expects several data readouts in the coming 14 months.
Source Fool.com
